<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45095">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717326</url>
  </required_header>
  <id_info>
    <org_study_id>5172-035</org_study_id>
    <secondary_id>2012-003354-89</secondary_id>
    <nct_id>NCT01717326</nct_id>
  </id_info>
  <brief_title>A Study of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)</brief_title>
  <acronym>C-WORTHy</acronym>
  <official_title>A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the safety and efficacy of MK-5172 in combination with MK-8742 ±
      ribavirin (RBV).  The primary efficacy endpoint will be Sustained Virologic Response 12
      weeks after the end of all study therapy (SVR12) in each of the treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A is being done in treatment-naïve (TN), genotype 1 (GT1), interferon eligible,
      non-cirrhotic (N-C) participants with chronic hepatitis C (CHC). Participants will be
      assigned randomly to 1 of 2 treatment arms in which they will receive MK-5172 100 mg once
      daily (QD) + MK-8742 20 mg or 50 mg QD and twice daily (BID) RBV, or to a treatment arm in
      which they will receive MK-5172 100 mg QD + MK-8742 50 mg QD without RBV. Treatment will
      last 12 weeks.

      In Part B, participants with hepatitis C virus (HCV) GT1 and HCV ribonucleic acid (RNA)
      levels of ≥10,000 IU/mL will be randomly assigned to a study arm, based on absence or
      presence of cirrhosis (C), whether they are TN or had poor response to previous antiviral
      therapy (null responders [NR]), or whether co-infected with human immunodeficiency virus
      (HIV); these participants will receive open-label MK-5172 (100 mg) in combination with
      MK-8742 (50 mg) ± RBV. Treatment will last 8 to 18 weeks dependent on arm assignment.

      In Part C, TN, N-C participants with HCV GT1b and HCV RNA levels of ≥10,000 IU/mL will be
      randomly assigned to receive open-label MK-5172 (100 mg) in combination with MK-8742 (50 mg)
      ± RBV. Treatment will last 8 weeks.

      In Part D, TN N-C participants with HCV GT3 and  HCV RNA levels of ≥10,000 IU/mL will be
      randomly assigned to receive open-label MK-5172 (100 mg) in combination with MK-8742 (50 mg)
      + RBV for 12 or 18 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing at least one Adverse Event (AE) on study</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study therapy due to an AE</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving undetectable HCV RNA at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving undetectable HCV RNA at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving undetectable HCV RNA at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving End-Of-Treatment Response (EOTR)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving Sustained Virologic Response 4 weeks after the end of all therapy (SVR4)</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Anticipated">610</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 20 mg+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a and GT1b participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a and GT1b participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1b only participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a only participants receive MK-5172 100 mg tablet orally QD for 8 weeks, MK-8742 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a only participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/C MK-5172+MK-8742 18 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742 18 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1a/non-a participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1b participants receive MK-5172 100 mg tablet orally QD for 8 weeks, MK-8742 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742 8wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT1b participants receive MK-5172 100 mg tablet orally QD for 8 weeks and MK-8742 50 mg capsule orally QD for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 participants receive MK-5172 100 mg tablet orally QD for 12 weeks, MK-8742 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GT3 participants receive MK-5172 100 mg tablet orally QD for 18 weeks, MK-8742 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5172</intervention_name>
    <description>100 mg tablet orally QD</description>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 20 mg+RBV</arm_group_label>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg+RBV</arm_group_label>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742 18 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742 18 wk</arm_group_label>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742 8wk</arm_group_label>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8742</intervention_name>
    <description>Part A: 20 or 50 mg capsule orally QD Part B: 50 mg capsule orally QD</description>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 20 mg+RBV</arm_group_label>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg+RBV</arm_group_label>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742 18 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742 18 wk</arm_group_label>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742 12 wk</arm_group_label>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742 8wk</arm_group_label>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to MK-8742 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)</description>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 20 mg+RBV</arm_group_label>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg+RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight</description>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 20 mg+RBV</arm_group_label>
    <arm_group_label>A: TN/N-C MK-5172+MK-8742 50 mg+RBV</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_label>B: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: TN/C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>B: NR/C/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <arm_group_label>B: TN/N-C/HIV MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>C: TN/N-C MK-5172+MK-8742+RBV 8 wk</arm_group_label>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 12 wk</arm_group_label>
    <arm_group_label>D: TN/N-C MK-5172+MK-8742+RBV 18 wk</arm_group_label>
    <other_name>Rebetol™</other_name>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        All participants - CHC genotype 1 (GT1) virus infection (Parts A, B, and C) or GT3 virus
        infection (Part D) - Female participants of childbearing potential or male participant
        with female partners of childbearing potential, must use two acceptable methods of birth
        control from ≥2 weeks prior to Day 1 until ≥6 months after last dose of study drug, or
        longer if dictated by local regulations

        Part A - Absence (no medical history or physical findings) of ascites, bleeding esophageal
        varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease, or
        cirrhosis - No evidence of advanced fibrosis, cirrhosis and/or hepatocellular carcinoma by
        biopsy or noninvasive testing (FibroScan and/or FibroTest)

        Parts B, C, and D - Treatment naïve with or without cirrhosis, or - Prior treatment
        failure to Peg-IFN/Ribavirin with or without cirrhosis, or - Co-infected with human
        immunodeficiency virus (HIV) without cirrhosis -Absence (no medical history or physical
        findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs
        or symptoms of advanced liver disease - Liver disease staging assessment by liver biopsy
        or noninvasive testing (FibroScan and/or FibroTest)

        Exclusion criteria:

        All participants - Non-GT1 HCV infection (Part A, Part B, and Part C) or a non-GT3 HCV
        infection (Part D) including a mixed GT infection (with a non-GT1 [Part A, Part B, and
        Part C] or non-GT3 [Part D]) or a non-typeable genotype - Evidence of hepatocellular
        carcinoma (HCC) or is under evaluation for HCC - Currently participating or participated
        in a study with an investigational compound within 30 days of signing informed consent and
        is not willing to refrain from participating in another study - Diabetic and/or
        hypertensive with clinically significant ocular examination findings - History of
        depression associated with hospitalization for depression, electroconvulsive therapy, or
        resulting in prolonged absence from work and/or significant disruption of daily functions
        - Suicidal or homicidal ideations and/or attempt, or history of severe psychiatric
        disorders - Clinical diagnosis of substance abuse - Current history of seizure disorder,
        stroke, or transient ischemic attack - Immunologically mediated disease - Chronic
        pulmonary disease - Clinically significant cardiac abnormalities/dysfunction - Active
        clinical gout within the last year - Hemoglobinopathy or myelodysplastic syndromes -
        History of organ transplants including hematopoietic stem cell transplants - Poor venous
        access - Indwelling venous catheter - History of gastric surgery or malabsorption
        disorders - Severe concurrent disease - Evidence of active or suspected malignancy, or a
        history of malignancy, ≤5 years before - Pregnant, lactating, expecting to conceive or
        donate eggs - Male participant with pregnant female partner - Member/family member of the
        investigational study or sponsor staff directly involved with this study - Evidence or
        history of chronic hepatitis not caused by HCV

        Part A - Not treatment-naïve - Documented to be HIV positive - Taking or planning to take
        significant inducers or inhibitors of CYP3A4 substrates or herbal supplements 2 weeks
        prior to start of study medications

        Parts B, C, and D - Previously received any HCV direct-acting antivirals - Requiring, or
        likely to require, chronic systemic administration of corticosteroids during the course of
        the trial - For participants diagnosed with diabetes mellitus, documented HbA1c &gt;8.5%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0367)</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>October 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
